GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Recordati SpA (OTCPK:RCDTF) » Definitions » PB Ratio

Recordati SpA (Recordati SpA) PB Ratio : 5.78 (As of May. 02, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Recordati SpA PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-02), Recordati SpA's share price is $51.60. Recordati SpA's Book Value per Share for the quarter that ended in Dec. 2023 was $8.93. Hence, Recordati SpA's PB Ratio of today is 5.78.

The historical rank and industry rank for Recordati SpA's PB Ratio or its related term are showing as below:

RCDTF' s PB Ratio Range Over the Past 10 Years
Min: 2.21   Med: 6.04   Max: 8.93
Current: 6

During the past 13 years, Recordati SpA's highest PB Ratio was 8.93. The lowest was 2.21. And the median was 6.04.

RCDTF's PB Ratio is ranked worse than
88.03% of 961 companies
in the Drug Manufacturers industry
Industry Median: 1.97 vs RCDTF: 6.00

During the past 12 months, Recordati SpA's average Book Value Per Share Growth Rate was 8.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 9.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 10.80% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 8.70% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Recordati SpA was 14.20% per year. The lowest was 3.70% per year. And the median was 9.25% per year.

Back to Basics: PB Ratio


Recordati SpA PB Ratio Historical Data

The historical data trend for Recordati SpA's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recordati SpA PB Ratio Chart

Recordati SpA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.24 7.28 8.44 5.13 5.15

Recordati SpA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.13 4.74 5.51 5.15 5.15

Competitive Comparison of Recordati SpA's PB Ratio

For the Drug Manufacturers - General subindustry, Recordati SpA's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Recordati SpA's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's PB Ratio distribution charts can be found below:

* The bar in red indicates where Recordati SpA's PB Ratio falls into.



Recordati SpA PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Recordati SpA's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=51.60/8.927
=5.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Recordati SpA  (OTCPK:RCDTF) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Recordati SpA PB Ratio Related Terms

Thank you for viewing the detailed overview of Recordati SpA's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Recordati SpA (Recordati SpA) Business Description

Traded in Other Exchanges
Address
Via Matteo Civitali 1, MIlan, ITA, 20148
Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.

Recordati SpA (Recordati SpA) Headlines

From GuruFocus

Recordati: Isturisa® (Osilodrostat) Approved In The U.S.

By PRNewswire PRNewswire 03-09-2020